National Cancer Institute (NCI): Endometrial Neoplasms trials

The registry lists 49 Endometrial Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 6 are open to participants now and 15 have results posted.

Phase 1 15Phase 2 24Phase 3 3No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingNCT07198074Phase 3
• Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerRecruitingNCT06253494Phase 1/2
• Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerRecruitingNCT05950464Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingNCT05112601Phase 2
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 2
• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerActive, not recruitingNCT03914612Phase 3Results posted
• ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaCompletedNCT03394027Phase 2Results posted
• Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial CancerActive, not recruitingNCT03367741Phase 2Results posted
• Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial CancerCompletedNCT03300557Phase 2Results posted
• Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial CancerCompletedNCT01307631Phase 2Results posted
• Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial CancerCompletedNCT01005329Phase 2Results posted
• A Study of Patients Receiving High-Dose Rate BrachytherapyCompletedNCT00924027Phase 2Results posted
• Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial CancerCompletedNCT00729586Phase 2Results posted
• Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00723255Phase 2Results posted
• VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00462826Phase 2Results posted
• Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial CancerCompletedNCT00416455Phase 1/2Results posted
• Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00301964Phase 2Results posted
• Lapatinib in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00096447Phase 2Results posted
• Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00095979Phase 2Results posted
• Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial CancerCompletedNCT00072176Phase 2Results posted
• Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersActive, not recruitingNCT05691504Phase 1
• Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554328Phase 2
• Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaActive, not recruitingNCT05256225Phase 3
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01935973Phase 1
• Endometrial Cancer Testing With Vaginal and Endometrial Cell SamplesCompletedNCT01793545
• Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial CancerCompletedNCT01440998Phase 1
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 1
• Endoxifen in Adults With Hormone Receptor Positive Solid TumorsCompletedNCT01273168Phase 1
• Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s CancersCompletedNCT01237067Phase 1
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid TumorsCompletedNCT01198184Phase 1
• Assessment of Screening Modalities for Gynecologic CancersCompletedNCT00879840
• Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00408655Phase 1
• A Follow-up Study of Women Evaluated and Treated for InfertilityCompletedNCT00342446
• Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With GeneticsCompletedNCT00341458
• Molecular Staging of Endometrial CancerCompletedNCT00340808
• Continuation of Follow-up of DES-Exposed CohortsCompletedNCT00340600
• Bone Mineral Density and Subsequent Cancer RiskCompletedNCT00340262
• Extended Follow-up of Columbia, MO Serum Bank ParticipantsCompletedNCT00340210
• Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial CancerCompletedNCT00339651
• EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial CancerCompletedNCT00107445Phase 2
• Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon CancerCompletedNCT00033358Phase 2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial CancerCompletedNCT00030485Phase 2
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsCompletedNCT00028535Phase 1
• Thalidomide in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00025467Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1